Iovance Biotherapeutics (IOVA) Stock Analysis & AI Equity Report

Medical - Pharmaceuticals USD Explore free reports

Iovance Biotherapeutics (IOVA) overview

Iovance Biotherapeutics (IOVA) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 264m and operating profit of USD -403m; the year-end share price was 2.73 USD and market capitalisation was USD 1,125m. Iovance Biotherapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Iovance Biotherapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 699mFY 2025
Share price2.73 USDFY 2025 year end
RevenueUSD 264mFY 2025
Operating profitUSD -403mFY 2025
Net earningsUSD -391mFY 2025
Market capitalisationUSD 1,125mFY 2025 year end

About Iovance Biotherapeutics

Iovance Biotherapeutics develops and commercializes tumor-infiltrating lymphocyte cell therapies for patients with solid tumor cancers. Its commercial products include Amtagvi, an individualized T-cell therapy for previously treated advanced melanoma, and Proleukin, an interleukin-2 product used in the Amtagvi treatment regimen and other applications. The company also develops TIL therapies and related approaches for additional solid tumor cancers, including lung cancer and sarcomas.

Generate the Iovance Biotherapeutics report

Iovance Biotherapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Iovance Biotherapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Iovance Biotherapeutics

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.